Skip to content
Precision for Medicine
Contact Us
Press Release

Precision Medicine Group joins McKesson's Oncology & Multispecialty segment. Read more in McKesson Business Highlights.

Read more
ON-DEMAND PANEL

Hear from One of Oncology’s Most Influential Regulatory Voices

Dr. Richard Pazdur joins Precision’s former FDA oncology leaders for a compelling panel conversation at ESMO 2026.

Few individuals have had a greater influence on modern oncology drug regulation than Dr. Richard Pazdur, former Director of the FDA Oncology Center of Excellence.

We were honored to provide a forum at ESMO for him to share his insights and perspectives, informed by more than 25 years at the FDA.

Dr. Pazdur was joined by Precision’s Dr. Harpreet Singh, Dr. Nicholas Richardson, and Dr. Paz Vellanki, all former FDA leaders in his oncology program, offering a rare opportunity to hear the stories behind pivotal regulatory initiatives and the lessons they offer sponsors today.

If you’re seeking expert guidance to better navigate evolving regulatory expectations and increasingly complex clinical trial decisions, this is a must-watch discussion. 

Some highlights you’ll hear:

  • Opportunities in the clinical research ecosystem to address trial complexity, slow patient accrual, and unnecessary bureaucracy

  • Why early multi-regional development is increasingly important

  • Why regulatory predictability matters to oncology investment 

Complete the form to watch the full panel recording!

Panelists

  • Richard Pazdur

    Richard Pazdur, MD

    Former Director, FDA Oncology Center of Excellence

    Dr. Pazdur is a leading figure in oncology drug regulation and the former Director of both the FDA’s Oncology Center of Excellence and the Center for Drug Evaluation and Research. Over his 26-year FDA career, he played a transformative role in modern cancer drug development, working closely with academic oncologists, industry partners, and regulatory scientists to streamline and strengthen the approval of innovative therapies.

    (SizeLimitingPyList: [linkedin])
  • Harpreet-Singh2

    Harpreet Singh, MD

    Chief Medical Officer and Former FDA Oncology Division Director

    Precision for Medicine

    Dr. Singh is an industry-leading oncologist and demonstrated medical leader in precision medicine, novel trial design and innovative regulatory initiatives designed to expedite drug approvals, drawing on nearly a decade leading oncology and rare disease programs at the FDA.

    (SizeLimitingPyList: [linkedin])
  • Nick Richardson

    Nicholas Richardson, DO, MPH

    Vice President, Clinical Development

    Precision for Medicine

    Dr. Richardson is an expert in hematology and oncology and a veteran of the FDA with almost nine years of experience, culminating as a Deputy Director for the Division of Hematologic Malignancies 2 where he spearheaded initiatives to develop novel endpoints in blood cancer.

    (SizeLimitingPyList: [linkedin])
  • Paz Vellanki

    Paz Vellanki, MD, PhD

    Vice President, Clinical Development, Oncology

    Precision for Medicine

    Dr. Vellanki brings first-hand insight into U.S. regulatory expectations as former Associate Director in the FDA’s Division of Oncology, where she oversaw drug development and regulatory decisions for therapeutics in lung cancer, head and neck cancer and rare tumors.

    (SizeLimitingPyList: [linkedin])